Evaluation of Safety and Therapeutic Efficacy of CAR-T Therapy
DOI:
https://doi.org/10.54097/r0e3nj91Keywords:
CAR-T cell therapy; leukemia, blood cancer, lymphomas.Abstract
Chimeric antigen receptor (CAR)-T therapy has been developed as revolutionary treatment in cancer treatment. It has been clinically proven to be effective and durable towards certain subtypes of blood cancer especially in B-cell leukemia or lymphoma. CARs are synthetic receptor which are designed to redirect T lymphocytes to eliminate cancer cells with a specific antigen on the surface. However, limited therapeutic efficacy and safety concern of CAR-T therapy present as obstacles to its application in both solid and hematological cancer. Hence more research is being conducted to study the mechanism behind therapeutic limitation and how to improve its therapeutic effectiveness. Furthermore, innovative strategies should be investigated to limit its toxicities. This review firstly explains the process of CAR-T therapy and its current milestone. Then the review discusses its current challenges and characterize some reasons for its limited therapeutic applications and strategies to improve its efficacy and safety in clinical settings.
Downloads
References
Chavez J C, Yassine F, Sandoval-Sus J, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: Current status and future directions. International Journal of Hematologic Oncology, 2021, 10(2): IJH33.
Sterner, R.C., Sterner, R.M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021, 11, 69 ...
Ren, A.; Tong, X.; Xu, N.; Zhang, T.; Zhou, F.; Zhu, H. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines 2023, 11, 165.
Harris, K., LaBelle, J.L. & Bishop, M.R. Current Status of CAR T Cell Therapy for Leukemias. Curr. Treat. Options in Oncol. 2021, 22, 62 ...
National Cancer Institute, CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers, https://www.cancer.gov/about-cancer/treatment/research/car-t-cells, 2023.
Wang, Z., Wu, Z., Liu, Y. et al. new development in CAR-T cell therapy. J Hematol Oncol 2017, 10, 53.
Carl H. June et al, CAR T cell immunotherapy for human cancer.Science. 2018, 359,1361-1365.
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.
FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019, 25(4):1142–6.
.Asmamaw Dejenie T, Tiruneh G/Medhin M, Dessie Terefe G, et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccines & Immunotherapeutics, 2022, 18(6): 2114254.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
